Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise

被引：66

作者：

Mai, Antonello ^{[1
]}

Rotili, Dante ^{[1
]}

Valente, Sergio ^{[1
]}

Kazantsev, Aleksey G. ^{[2
]}

机构：

[1] Univ Roma La Sapienza, Inst Pasteur, Cenci Bolognetti Fdn, Dept Drug Chem & Technol, I-00185 Rome, Italy

[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Charlestown, MA 02129 USA

来源：

CURRENT PHARMACEUTICAL DESIGN | 2009年 / 15卷 / 34期

关键词：

Epigenetics; HDAC inhibitors; neurodegenerative disorders; Huntington's disease; Alzheimer's disease; Parkinson disease; amyotrophic lateral sclerosis; spinal muscular atrophy; Friedreich's ataxia; SPINAL MUSCULAR-ATROPHY; SUBEROYLANILIDE HYDROXAMIC ACID; INCREASES SMN EXPRESSION; CORTICAL LEWY BODIES; ALPHA-SYNUCLEIN; VALPROIC ACID; ALZHEIMERS-DISEASE; MOUSE MODEL; HUNTINGTONS-DISEASE; NEURONAL SURVIVAL;

D O I：

10.2174/138161209789649349

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Neurodegenerative disorders (NDs) such as Huntington's disease, Alzheimer's disease, Parkinson disease, amyotrophic lateral sclerosis, spinal muscular atrophy, Friedreich's ataxia, and others are multi-factorial illnesses, in which many pathways (still poorly understood) act serially and in parallel to give a determined pathologic phenotype. Thus, presently there are no effective cures for these diseases. Some phenotypic as well as mechanistic features, common to the most of NDs, can be linked to epigenetic defects, that can lead to alteration of acetylation homeostasis and impairment of the histone acetyltransferase (HAT): histone deacetylase (HDAC) balance. Here we survey most of the recent applications of HDAC inhibitors in the cited NDs, and we make the point of our (up to now) knowledge about the involvement of singular HDAC/SIRT isoform in NDs and other CNS pathologies.

引用

页码：3940 / 3957

页数：18

共 119 条

[1]

Alim MA, 2004, J ALZHEIMERS DIS, V6, P435

[2] Phenylbutyrate increases SMN expression in vitro:: relevance for treatment of spinal muscular atrophy [J].